323 related articles for article (PubMed ID: 34402243)
1. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
Kim SS; Lee S; Kim MJ
Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas.
Min JH; Kim SH; Hwang JA; Hyun SH; Ha SY; Choi SY; Kim SW; Kim HS
Eur Radiol; 2021 Jun; 31(6):3649-3660. PubMed ID: 33211142
[TBL] [Abstract][Full Text] [Related]
4. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
[TBL] [Abstract][Full Text] [Related]
5. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
[TBL] [Abstract][Full Text] [Related]
6. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
[TBL] [Abstract][Full Text] [Related]
7. A Modified Targetoid Feature Emphasizing Thin-Rim APHE to Improve the Diagnostic Performance of LI-RADS for Malignant Hepatic Tumors.
Huang R; Zheng C; Xu G; Chen X; Shen J; Mao S
J Hepatocell Carcinoma; 2024; 11():775-786. PubMed ID: 38689802
[TBL] [Abstract][Full Text] [Related]
8. LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation.
Min JH; Lee MW; Rhim H; Han S; Song KD; Kang TW; Jeong WK; Cha DI; Kim JM; Choi GS; Kim K
Eur Radiol; 2024 Jan; 34(1):525-537. PubMed ID: 37526668
[TBL] [Abstract][Full Text] [Related]
9. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
[TBL] [Abstract][Full Text] [Related]
10. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
[TBL] [Abstract][Full Text] [Related]
11. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
[TBL] [Abstract][Full Text] [Related]
12. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.
Vernuccio F; Cannella R; Meyer M; Choudhoury KR; Gonzáles F; Schwartz FR; Gupta RT; Bashir MR; Furlan A; Marin D
AJR Am J Roentgenol; 2019 Aug; 213(2):W57-W65. PubMed ID: 31039012
[No Abstract] [Full Text] [Related]
13. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
[TBL] [Abstract][Full Text] [Related]
14. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI.
Choi SH; Lee SS; Park SH; Kim KM; Yu E; Park Y; Shin YM; Lee MG
Radiology; 2019 Feb; 290(2):388-397. PubMed ID: 30422088
[TBL] [Abstract][Full Text] [Related]
15. Recurrence After Curative Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: Diagnostic Algorithms on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.
Wang W; Yang C; Zhu K; Yang L; Ding Y; Luo R; Zhu S; Chen C; Sun W; Zeng M; Rao SX
Liver Transpl; 2020 Jun; 26(6):751-763. PubMed ID: 31901208
[TBL] [Abstract][Full Text] [Related]
16. A multivariate model based on gadoxetic acid-enhanced MRI using Li-RADS v2018 and other imaging features for preoperative prediction of dual‑phenotype hepatocellular carcinoma.
Liu MT; Zhang JY; Xu L; Qu Q; Lu MT; Jiang JF; Zhao XC; Zhang XQ; Zhang T
Radiol Med; 2023 Nov; 128(11):1333-1346. PubMed ID: 37740839
[TBL] [Abstract][Full Text] [Related]
17. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery.
Kang HJ; Kim H; Lee DH; Hur BY; Hwang YJ; Suh KS; Han JK
Radiology; 2021 Sep; 300(3):572-582. PubMed ID: 34227881
[TBL] [Abstract][Full Text] [Related]
18. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
[TBL] [Abstract][Full Text] [Related]
19. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy.
Min JH; Lee MW; Park HS; Lee DH; Park HJ; Lee JE; Park SJ; Kim SS; Park SH; Ha SY; Hwang JA; Cha DI; Park B
AJR Am J Roentgenol; 2022 Sep; 219(3):421-432. PubMed ID: 35319906
[No Abstract] [Full Text] [Related]
20. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study.
Lee S; Kim KW; Jeong WK; Jeong SY; Hwang JA; Choi JS; Lee SG; Joh JW
Ann Surg Oncol; 2021 Oct; 28(11):6782-6789. PubMed ID: 33751296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
